moclobemide has been researched along with Diffuse Myofascial Pain Syndrome in 3 studies
Moclobemide: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.
moclobemide : A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To study the usefulness of moclobemide and amitriptyline in the treatment of fibromyalgia (FM) in females without psychiatric disorder." | 9.08 | A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder. ( Hannonen, P; Isomeri, R; Malminiemi, K; Roponen, P; Yli-Kerttula, U, 1998) |
| "To study the usefulness of moclobemide and amitriptyline in the treatment of fibromyalgia (FM) in females without psychiatric disorder." | 5.08 | A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder. ( Hannonen, P; Isomeri, R; Malminiemi, K; Roponen, P; Yli-Kerttula, U, 1998) |
| "Fibromyalgia (FM) syndrome is a chronic condition of unknown aetiology characterised by musculoskeletal pain that often co-exists with sleep disturbance, cognitive dysfunction and fatigue." | 2.48 | Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome. ( Nishishinya, MB; Tort, S; Urrútia, G; Walitt, B, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tort, S | 1 |
| Urrútia, G | 1 |
| Nishishinya, MB | 1 |
| Walitt, B | 1 |
| Zijlstra, TR | 1 |
| van de Laar, MA | 1 |
| Hannonen, P | 1 |
| Malminiemi, K | 1 |
| Yli-Kerttula, U | 1 |
| Isomeri, R | 1 |
| Roponen, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cannabidiol for Fibromyalgia -The CANNFIB Trial Protocol for a Randomized, Double-blind, Placebo-controlled, Parallel-group, Single-center Trial[NCT04729179] | Phase 3 | 200 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for moclobemide and Diffuse Myofascial Pain Syndrome
| Article | Year |
|---|---|
Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome.
Topics: Adult; Carbazoles; Fibromyalgia; Humans; Moclobemide; Monoamine Oxidase Inhibitors; Randomized Contr | 2012 |
1 trial available for moclobemide and Diffuse Myofascial Pain Syndrome
| Article | Year |
|---|---|
A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder.
Topics: Adolescent; Adult; Aged; Amitriptyline; Analgesics; Antidepressive Agents, Tricyclic; Benzamides; Di | 1998 |
1 other study available for moclobemide and Diffuse Myofascial Pain Syndrome
| Article | Year |
|---|---|
The lack of a placebo effect in a trial of fluoxetine in the treatment of fibromyalgia.
Topics: Amitriptyline; Antidepressive Agents; Antidepressive Agents, Second-Generation; Female; Fibromyalgia | 2002 |